v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Cash flows from operating activities:          
Net income (loss) $ 6,017 $ 1,731 $ 11,678 $ 11,832  
Adjustments for noncash items:          
Depreciation     9,857 10,018  
Amortization of identifiable intangibles     879 879  
Reduction of right-of-use leased assets     1,096 1,064  
Deferred income taxes     1,956 1,209  
Accrued pension and post-retirement benefits     63 107  
Stock-based compensation expense     256 919  
Gain on the sale of assets     0 (1,492)  
Gain on the sale of divested business 0 0 (565) (9,657) $ 74,900
Changes in assets and liabilities:          
Accounts and other receivables     (15,637) (14,016)  
Inventories     (23,101) (15,263)  
Income taxes recoverable/payable     (176) (349)  
Prepaid expenses and other     7,531 8,897  
Accounts payable and accrued expenses     14,559 2,336  
Lease liability     (1,286) (1,240)  
Pension and postretirement benefit plan contributions     (58) (291)  
Other, net     625 2,195  
Net cash provided by (used in) operating activities     7,677 (2,852)  
Cash flows from investing activities:          
Capital expenditures     (9,266) (5,638)  
Proceeds from the sale of Terphane     565 9,835  
Proceeds from the sale of assets     0 1,904  
Net cash (used in) provided by investing activities     (8,701) 6,101  
Cash flows from financing activities:          
Borrowings     105,900 88,197  
Debt principal payments     (94,962) (87,494)  
Debt financing costs     0 (1,272)  
Net cash provided by (used in) financing activities     10,938 (569)  
Effect of exchange rate changes on cash     536 53  
Increase (decrease) in cash and cash equivalents     10,450 2,733  
Cash and cash equivalents at beginning of period     6,729 7,062  
Cash and cash equivalents at end of period $ 17,179 $ 9,795 $ 17,179 $ 9,795 $ 7,062